Drugs that contain Afatinib Dimaleate

1. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(3 years from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(7 years from now)

CN101402631A BOEHRINGER INGELHEIM Amino Quinazoline Dimaleate, Method For Production Thereof And Use Thereof
Dec, 2013

(8 years ago)

CN1481370A BOEHRINGER INGELHEIM Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture
Dec, 2021

(9 months ago)

CN1277822C BOEHRINGER INGELHEIM Quinazoline Derivatives, Pharmaceutical Compositions Containing These Compounds, Their Use And Process For Their Manufacture
Dec, 2021

(9 months ago)

CN1867564A BOEHRINGER INGELHEIM Method For Preparing Amino Croton Radical Compound
Oct, 2024

(2 years from now)

CN1867564B BOEHRINGER INGELHEIM Method For Preparing Amino Croton Based Compound
Oct, 2024

(2 years from now)

IN224186B BOEHRINGER INGELHEIM Quinazoline Compounds And Process Thereof
Dec, 2021

(9 months ago)

IN200300822P1 BOEHRINGER INGELHEIM Quinazoline Compounds And Process Thereof
Dec, 2021

(9 months ago)

EP2508521B1 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP2508521A2 BOEHRINGER INGELHEIM Dimaleat Of An Amino Crotonyl Compound And Method Of Production Thereof
Oct, 2024

(2 years from now)

EP1678165B1 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP2508521A3 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP1678165A2 BOEHRINGER INGELHEIM Method For The Production Of Amino Crotonyl Compounds
Oct, 2024

(2 years from now)

EP1345910B1 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

EP1345910A1 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

EP1345910B9 BOEHRINGER INGELHEIM Quinazoline Derivatives, Medicaments Containing Said Compounds, Their Utilization And Method For The Production Thereof
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them Jul, 2026

(3 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases Nov, 2026

(4 years from now)

US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases May, 2027

(4 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992 Dec, 2029

(7 years from now)

US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds Apr, 2030

(7 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992 Jun, 2030

(7 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient Jul, 2030

(7 years from now)

US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient Jan, 2031

(8 years from now)

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.